SANUWAVE’s CE-marked orthoPACE devices sold fewer units in 2012, partially due to the European economic downturn, according to the release.
The company’s research and development cost $1.8 million over the past year compared with $2.7 million in 2011, a 35 percent decrease, due to lower clinical results expenses.
More Articles on Devices:
7 New Orthopedic Device Launches & Releases
Amedica Valeo Interbody Fusion Device Hits 10k Implantations
Baptist Medical Center Acquires Renaissance Spine System
